Cannabis, diabetes and mortality

Researchers from Taiwan, Jordan and the US found that cannabis use linked to substantially higher risks of mortality, cardiovascular events, and adverse kidney outcomes among patients with type 2 diabetes mellitus initiating GLP−1 RA therapy. Clinicians should inquire about cannabis use when initiating GLP−1 RA therapy and counsel patients regarding potential risks.